期刊
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
卷 15, 期 9, 页码 1251-1264出版社
OXFORD UNIV PRESS
DOI: 10.1017/S1461145711001830
关键词
Cannabinoids; CB1 receptors; mu-opioid receptors; naltrexone; opioids; tetrahydrocannabinol; THC
资金
- VA Schizophrenia Center
- Yale University School of Medicine from Lilly
- Yale University School of Medicine from Astra Zeneca
- Abbott Laboratories
- Eli Lilly Inc.
- Organon
- Pfizer Inc.
- Sanofi
Although a wealth of preclinical evidence indicates an interplay between the mu-opioid (MOR) and cannabinoid 1 receptor (CB1R) systems, the precise nature of the cross modulation in humans is unclear. The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Delta(9)-tetrahydrocannabinol (THC), in healthy human subjects. Healthy human subjects, screened carefully for any medical or psychiatric illness, were administered either placebo or active naltrexone (25 mg) orally on each test day, followed 45 mm later by placebo and 165 min later by active i.v. THC (0.025 mg/kg) in a randomized, fixed-order, double-blind manner. Subjective, behavioural and cognitive effects were assessed before and at several points after each drug administration. THC produced expected effects, including euphoria, anxiety, transient perceptual alterations, transient psychotomimetic effects and cognitive impairments. However, naltrexone did not produce any effects alone, nor did it attenuate any of THC's effects. Thus, in healthy human subjects who use cannabis intermittently, MOR antagonism does not modulate the common acute subjective, behavioural and cognitive effects of THC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据